SEARCH

SEARCH BY CITATION

References

  • 1
    Roland M, Berstad A, Liavåg I. A histological study of gastric mucosa before and after proximal gastric vagotomy in duodenal ulcer patients. Scan J Gastroenterol 1975; 10: 181 6.
  • 2
    Jönsson KÄ, Ström M, Bodemar G, Norrby K. Histological changes in the gastroduodenal mucosa after long-term medical treatment with cimetidine or parietal cell vagotomy in patients with juxtapyloric ulcer disease. Scand J Gastroenterol 1988; 23: 433 41.
  • 3
    Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161 7.
  • 4
    Lamberts R, Creutzfeldt W, Strüber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356 70.
  • 5
    Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or funduplication. N Engl J Med 1996; 304: 1018 22.
  • 6
    Geboes K, Ectors N, Penson J, Leuven KU. Long-term lansoprazole treatment in man: effects on gastric mucosa histology. Gastroenterology 1995; 108: A99.
  • 7
    Baldi F, Bardhan KD, Bormann PC, et al. Lansoprazole maintains healing in patients with reflux esophagitis. Gastroenterology 1996; 254: A42.
  • 8
    Price AB. The Sydney system: histological division. J Gastroenterol Hepatol 1991; 6: 209 22.
  • 9
    Stolte M, Stadelmann O, Bethke B, Burkhard G. Relationship between the degree of Helicobacter pylori colonization and the degree and activity of gastritis, surface epithelial degeneration and mucus secretion. Z Gastroenterol 1995; 33: 89 93.
  • 10
    Solcia E, Villani L, Fiocca R, et al. Effect of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol 1994; 29(Suppl. 201): 28 34.
  • 11
    Logan RPH, Walker MM, Misiewics JJ, et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995; 36: 12 16.
  • 12
    Stolte M & Bethke B. Elimination of Helicobacter pylori under treatment with omeprazole. Z Gastroenterol 1990; 28: 271 4.
  • 13
    Graham DY, Genta R, Evans DG, et al. Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole. Am J Gastroenterol 1996; 91: 2120 34.
  • 14
    Meining A & Stolte M. H2-receptor-antagonists as well as antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients. Aliment Pharmacol Ther 1997; 11: 729 34.
  • 15
    Stolte M, Baumann H, Bethke B, Lauer E, Ritter M. Active autoimmune gastritis without total atrophy of the glands. Z Gastroenterol 1992; 30: 729 33.
  • 16
    Faller G, Steininger H, Eck M, et al. Antigastric autoantibodies in Helicobacter pylori gastritis: prevalence, in-situ binding sites and clues for clinical relevance. Virchows Arch 1996, 427(5): 483 6.
  • 17
    Negrini R, Savio A, Poiesi C, et al. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology 1996; 111: 655 65.
  • 18
    Stolte M, Bethke B, Blum AL, Sulser E, Stadelmann O. Antacid treatment has a deleterious effect on the severity and activity of gastritis of the corpus mucosa. Ir J Med Sci 1992; 161 (Suppl 10): 6(Abstract).
  • 19
    Möller H, Nissen A, Mosbech J. Use of cimetidine and other peptic ulcer drugs in Denmark 1977–1990 with analysis of the risk of gastric cancer among cimetidine users. Gut 1992; 33: 1166 9.
  • 20
    La Vecchia C, Negri E, D’avanzo B, Franceschi S. Histamine-2-receptor antagonists and gastric cancer risk. Lancet 1990; 336: 355 7.
  • 21
    Caygill CPJ, Knowles RL, Hall R. Increased risk of cancer mortality after vagotomy for peptic ulcer: a preliminary analysis. Eur J Cancer Prev 1991; 1: 35 7.
  • 22
    Lundegård G, Ekbom A, McLaughlin JK, Nyren O. Gastric cancer risk after vagotomy. Gut 1994; 35: 946 9.
  • 23
    Meining A, Bayerdörffer E, Hatz R, et al. Different expression of Helicobacter pylori gastritis in gastric cancer patients. Gut 1995; 37(Suppl. 1): 154A.
  • 24
    Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997, 112: 707 17.
  • 25
    Meining A, Stolte M, Müller P, et al. Gastric carcinoma risk index in patients infected with Helicobacter pylori. Gastroenterology 1996; 110: A556.
  • 26
    Meining A & Stolte M. Different expression of H. pylori-gastritis in relatives of gastric carcinoma patients . Gut 1996; 39 (Suppl. 2): A17 18.